前收市價 | 8.20 |
開市 | 8.16 |
買盤 | 8.05 x 0 |
賣出價 | 8.06 x 0 |
今日波幅 | 7.97 - 8.25 |
52 週波幅 | 3.84 - 15.50 |
成交量 | |
平均成交量 | 2,331,023 |
市值 | 439.042M |
Beta 值 (5 年,每月) | 2.65 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -79.20 |
業績公佈日 | 2024年6月12日 - 2024年6月17日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 7.83 |
Recently, the cannabis market received the best hoped-for news. The Drug Enforcement Administration (DEA) announced it is moving forward with plans to reschedule marijuana from a Schedule I to a Schedule III controlled substance. While this excited many investors, the cannabis market is still a ways away from full federal legalization. While the DEA’s announcement has led to a surge in cannabis stocks, companies facing pre-existing challenges are unlikely to see immediate improvements. In partic
Investors should not get overly excited about President Biden’s decision to reclassify marijuana. The potential move toward becoming a less dangerous schedule 3 drug is lengthy and will not result in cannabis becoming federally legal. That has important implications in relation to access to financing for cannabis firms among other things. This has led to investors considering if there are any cannabis stocks to sell as the road to Federal legalization is still long. Nothing has changed following
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?